Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5‐Year Retrospective Cohort Study
The Journal of Clinical Pharmacology · 2023
DOI: 10.1002/jcph.2204 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Clinical Pharmacology, 2023. Verfasst von Tomohiro Aigami und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Four direct oral anticoagulants (DOACs) are used in Japan (edoxaban, rivaroxaban, apixaban, and dabigatran); however, few studies have examined the long‐term treatment persistence of these DOACs. Furthermore, the factors associated with persistence remain unclear. This single‐center, retrospective cohort study enrolled participants who were newly prescribed the 4 DOACs between January 1, 2012, and April 30, 2020. We assessed the treatment persistence rate by calculating the cumulative incidence rate of prescription switch or discontinuation for 5 years from the initial prescription. The factors associated with persistence were examined using multivariate analysis. The edoxaban was used as a reference for comparison with the other DOACs. The persistence rate at 5 years was 52.9% for all DOACs, including 67.0%, 51.6%, 50.2%, and 37.0% for edoxaban, rivaroxaban, apixaban, and dabigatran, respectively. Multivariate analysis revealed that age >65 years (hazard ratio [HR], 0.62 [95%CI, 0.41–0.93]), chronic kidney disease (HR, 1.63 [95%CI, 1.11–2.39]), baseline hemoglobin (HR, 0.85 [95%CI, 0.78–0.93]), diabetes mellitus (HR, 0.51 [95%CI, 0.29–0.93]), and type of DOACs (rivaroxaban: HR, 1.81 [95%CI, 1.03–3.18]; apixaban: HR, 2.00 [95%CI, 1.15–3.48]; and dabigatran: HR, 2.84 [95%CI, 1.66–4.86]) were significantly associated with nonpersistence at 1 year. At 5 years, diabetes mellitus (HR, 0.60 [95%CI, 0.37–0.97]) and type of DOAC were significantly associated with nonpersistence (rivaroxaban: HR, 1.79 [95%CI, 1.09–2.94]; apixaban: HR, 2.04 [95%CI, 1.26–3.31]; and dabigatran: HR, 2.76 [1.73–4.42]). Long‐term treatment persistence differed according to the type of DOAC, with edoxaban exhibiting the highest level of persistence. The factors associated with persistence may change over the treatment course, but larger studies are required to generalize our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan.
- Department of Pharmacy, National Hospital Organization Fukuyama Medical Center, Fukuyama, Japan.
- Department of Cardiovascular, Renal, and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Public Health, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Division of Rehabilitation, Sapporo Medical University School of Medicine, Sapporo, Japan.
ORCID-Profile: Tomoyuki Ishigo, Satoshi Katano, Masahide Fukudo
Zitieren
APA
Aigami, T., Ishigo, T., Takada, R., Yano, T., Koyama, M., Katano, S., Fujii, S., & Fukudo, M. (2023). Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5‐Year Retrospective Cohort Study. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2204
Vancouver
Aigami T, Ishigo T, Takada R, Yano T, Koyama M, Katano S, et al. Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5‐Year Retrospective Cohort Study. The Journal of Clinical Pharmacology. 2023. doi:10.1002/jcph.2204
BibTeX
@article{Aigami2023,
author = {Aigami, Tomohiro and Ishigo, Tomoyuki and Takada, Ryo and Yano, Toshiyuki and Koyama, Masayuki and Katano, Satoshi and Fujii, Satoshi and Fukudo, Masahide},
title = {Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5‐Year Retrospective Cohort Study},
journal = {The Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1002/jcph.2204}
}
EUVIMED